CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease. Therapeutic Advances In Medical Oncology 2018, 10: 1758835918818346. PMID: 30619511, PMCID: PMC6299331, DOI: 10.1177/1758835918818346.Peer-Reviewed Original ResearchTriple-negative breast cancerProgression-free survivalBreast cancerCDK4/6 inhibitorsHormone receptor-positive HER2-negative diseaseCyclin-dependent kinase 4/6 inhibitorsPositive human epidermal growth factor receptor 2Human epidermal growth factor receptor 2Epidermal growth factor receptor 2HER2-negative diseaseGrowth factor receptor 2Metastatic breast cancer therapyNegative breast cancerBreast cancer therapyFactor receptor 2Preclinical evidenceClinical dataReceptor 2Later linesHormone receptorsCancerCancer therapyCell linesInhibitorsCDK inhibitors